About
Small molecule for neurological disorders
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
5
As Collaborator
3
Total Enrollment
578
By Phase
PHASE2: 6PHASE2/PHASE3: 2
By Status
COMPLETED: 6RECRUITING: 2
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06673368Lead Sponsor
A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder
PHASE2Recruiting
60 participants
Started: Feb 25, 2025 · Completed: Nov 30, 2025
NCT06215144Lead Sponsor
Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD
PHASE2/PHASE3Recruiting
160 participants
Started: Jan 25, 2024 · Completed: Feb 1, 2026
NCT05683249Lead Sponsor
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
PHASE2/PHASE3Completed
223 participants
Started: Feb 25, 2023 · Completed: Jan 17, 2024
NCT04762017Collaborator
OCS-05 in Patients With Optic Neuritis
PHASE2Completed
36 participants
Started: Feb 10, 2021 · Completed: Sep 16, 2024
NCT03601169Lead Sponsor
Comparison of MMFS Dosages in Older Adults
PHASE2Completed
9 participants
Started: Jul 23, 2018 · Completed: Jan 31, 2019
Locations (1)
Headquarters
Walnut Creek, CA, United States
Map
Loading map...